{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:50:51Z","timestamp":1787003451390,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    \u03b2-blocker therapy has been positively associated with improved survival in patients undergoing oncologic colorectal resection. This study investigates if the type of \u03b2-blocker used affects\u00a090-day postoperative mortality following colon cancer surgery. The study was designed as a nationwide retrospective cohort study including all adult (\u2265\u200918\u00a0years\u00a0old) patients with ongoing \u03b2-blocker therapy who underwent elective and emergency colon cancer surgery in Sweden between January 1, 2007 and December 31, 2017. Patients were divided into four cohorts: metoprolol, atenolol, bisoprolol, and other beta-blockers. The primary outcome of interest was 90-day postoperative mortality. A Poisson regression model with robust standard\u00a0errors was used, while adjusting for all clinically relevant variables, to determine the association between different \u03b2-blockers and 90-day postoperative mortality. A total of 9254 patients were included in the study. There was no clinically significant difference in crude 90-day postoperative mortality rate [n (%)] when comparing the four beta-blocker cohorts metoprolol, atenolol, bisoprolol and other beta-blockers. [97 (1.8%) vs. 28 (2.0%) vs. 29 (1.7%) vs. 11 (1.2%),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.670]. This remained unchanged when adjusting for relevant covariates in the Poisson regression model. Compared to metoprolol, there was no statistically significant decrease in the risk of 90-day postoperative mortality with atenolol [adj. IRR (95% CI): 1.45 (0.89\u20132.37),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.132], bisoprolol [adj. IRR (95% CI): 1.45 (0.89\u20132.37),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.132], or other beta-blockers [adj. IRR (95% CI): 0.92 (0.46\u20131.85),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.825]. In patients undergoing colon cancer surgery, the risk of\u00a090-day postoperative mortality does not differ between the investigated types of \u03b2-adrenergic blocking agents.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-08736-6","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T22:05:16Z","timestamp":1648505116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery"],"prefix":"10.1038","volume":"12","author":[{"given":"Lovisa","family":"Ekestubbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary Alan","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian Peter","family":"Forssten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Sj\u00f6lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Matthiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Ahl Hulme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"8736_CR1","unstructured":"Colorectal Cancer Report. A report from the Swedish Colorectal Cancer Registry aimed toward patients and the general public (Swedish) [Tarmcancerrapport 2019. En rapport fr\u00e5n Svenska Kolorektalcancerregistret som riktar sig till patienter och allm\u00e4nheten] Regional Cancer Centre North\u00a02019. https:\/\/cancercentrum.se\/globalassets\/cancerdiagnoser\/tjock-och-andtarm-anal\/kvalitetsregister\/tjock-och-andtarm-2020\/patientrapport-2019-kolorektal.pdf. Last accessed 22 January 2021."},{"key":"8736_CR2","unstructured":"Colon Cancer. National quality report 2019 from the Swedish Colorectal Cancer Registry (Swedish) [Koloncancer 2019. Nationell kvalitetsrapport f\u00f6r \u00e5r 2019 fr\u00e5n Svenska Kolorektalcancerregistret] Regional Cancer Centre North\u00a02019. Available at: https:\/\/cancercentrum.se\/globalassets\/cancerdiagnoser\/tjock--och-andtarm-anal\/kvalitetsregister\/tjock--och-andtarm-2020\/kolonrapport-2019.pdf. Last accessed 21 January 2021) \u2019."},{"key":"8736_CR3","unstructured":"D\u00f6dlighet i tjock-och \u00e4ndtarmscancer\u2014Folkh\u00e4lsomyndigheten. https:\/\/www.folkhalsomyndigheten.se\/folkhalsorapportering-statistik\/tolkad-rapportering\/folkhalsans-utveckling\/resultat\/halsa\/dodlighet-i-tjock-och-andtarmscancer\/."},{"key":"8736_CR4","first-page":"89","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla, P., Sunkara, T. & Barsouk, A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz. Gastroenterol. 14, 89\u2013103 (2019).","journal-title":"Prz. Gastroenterol."},{"key":"8736_CR5","unstructured":"Screening f\u00f6r tjock-och \u00e4ndtarmscancer\u2014Rekommendation och bed\u00f6mningsunderlag. 20."},{"key":"8736_CR6","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMsr1714643","volume":"378","author":"B Lauby-Secretan","year":"2018","unstructured":"Lauby-Secretan, B., Vilahur, N., Bianchini, F., Guha, N. & Straif, K. The IARC perspective on colorectal cancer screening. N. Engl. J. Med. 378, 1734\u20131740 (2018).","journal-title":"N. Engl. J. Med."},{"key":"8736_CR7","unstructured":"Hultcrantz, R. et al. Nationella arbetsgruppen f\u00f6r utredning om inf\u00f6rande av allm\u00e4n tarmcancerscreening. 9."},{"key":"8736_CR8","unstructured":"The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017\u2014The Lancet Gastroenterology & Hepatology. https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(19)30345-0\/fulltext."},{"key":"8736_CR9","doi-asserted-by":"publisher","first-page":"e036164","DOI":"10.1136\/bmjopen-2019-036164","volume":"10","author":"R Ahl","year":"2020","unstructured":"Ahl, R. et al. Effects of beta-blocker therapy on mortality after elective colon cancer surgery: A Swedish nationwide cohort study. BMJ Open 10, e036164 (2020).","journal-title":"BMJ Open"},{"key":"8736_CR10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/bjs.10988","volume":"106","author":"R Ahl","year":"2019","unstructured":"Ahl, R. et al. Effect of beta-blocker therapy on early mortality after emergency colonic cancer surgery. BJS (Br. J. Surg.) 106, 477\u2013483 (2019).","journal-title":"BJS (Br. J. Surg.)"},{"key":"8736_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/SLA.0000000000002970","volume":"271","author":"R Ahl","year":"2020","unstructured":"Ahl, R. et al. \u03b2-blockade in rectal cancer surgery: A simple measure of improving outcomes. Ann. Surg. 271, 140\u2013146 (2020).","journal-title":"Ann. Surg."},{"key":"8736_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00068-017-0779-5","volume":"43","author":"R Ahl","year":"2017","unstructured":"Ahl, R. et al. \u03b2-blocker after severe traumatic brain injury is associated with better long-term functional outcome: A matched case control study. Eur. J. Trauma Emerg. Surg. 43, 783\u2013789 (2017).","journal-title":"Eur. J. Trauma Emerg. Surg."},{"key":"8736_CR13","doi-asserted-by":"crossref","unstructured":"POISE Study Group et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 371, 1839\u20131847 (2008).","DOI":"10.1016\/S0140-6736(08)60601-7"},{"key":"8736_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004476.pub2","author":"H Blessberger","year":"2014","unstructured":"Blessberger, H. et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD004476.pub2 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"8736_CR15","first-page":"1061","volume":"64","author":"RS Friese","year":"2008","unstructured":"Friese, R. S., Barber, R., McBride, D., Bender, J. & Gentilello, L. M. Could beta blockade improve outcome after injury by modulating inflammatory profiles?. J. Trauma 64, 1061\u20131068 (2008).","journal-title":"J. Trauma"},{"key":"8736_CR16","doi-asserted-by":"crossref","unstructured":"Bangalore, S., Wetterslev, J., Pranesh, S., Sawhney, S. & Messerli, C. G. Perioperative beta blockers in patients having non-cardiac surgery: A meta-analysis. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] (Centre for Reviews and Dissemination (UK), 2008).","DOI":"10.1016\/S0140-6736(08)61560-3"},{"key":"8736_CR17","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/0002-8703(84)90583-0","volume":"108","author":"AJ Wood","year":"1984","unstructured":"Wood, A. J. Pharmacologic differences between beta blockers. Am. Heart J. 108, 1070\u20131077 (1984).","journal-title":"Am. Heart J."},{"key":"8736_CR18","doi-asserted-by":"crossref","unstructured":"\u00c5gesen, F. N., Weeke, P. E., Tfelt\u2010Hansen, P. & Tfelt\u2010Hansen, J. Pharmacokinetic variability of beta\u2010adrenergic blocking agents used in cardiology. Pharmacol Res Perspect 7, e00496 (2019).","DOI":"10.1002\/prp2.496"},{"key":"8736_CR19","first-page":"168","volume":"7","author":"B Lemmer","year":"1982","unstructured":"Lemmer, B. Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author\u2019s transl). Herz 7, 168\u2013178 (1982).","journal-title":"Herz"},{"key":"8736_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.tips.2011.02.010","volume":"32","author":"JG Baker","year":"2011","unstructured":"Baker, J. G., Hill, S. J. & Summers, R. J. Evolution of \u03b2-blockers: From anti-anginal drugs to ligand-directed signalling. Trends Pharmacol. Sci. 32, 227\u2013234 (2011).","journal-title":"Trends Pharmacol. Sci."},{"key":"8736_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/0002-8703(82)90127-2","volume":"104","author":"J Meier","year":"1982","unstructured":"Meier, J. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. Am. Heart J. 104, 364\u2013373 (1982).","journal-title":"Am. Heart J."},{"key":"8736_CR22","unstructured":"Swedish Colorectal Cancer Registry (SCRCR)\u2014Nationella Kvalitetsregister [Internet]. [cited 2020 Nov 9]. https:\/\/kvalitetsregister.se\/englishpages\/findaregistry\/registerarkivenglish\/swedishcolorectalcancerregistryscrcr.2156.html."},{"key":"8736_CR23","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2008. http:\/\/www.R-project.org\/."},{"issue":"Suppl 4","key":"8736_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/00005344-198608004-00002","volume":"8","author":"BN Prichard","year":"1986","unstructured":"Prichard, B. N. & Tomlinson, B. The additional properties of beta adrenoceptor blocking drugs. J. Cardiovasc. Pharmacol. 8(Suppl 4), S1-15 (1986).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"8736_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/TA.0000000000001747","volume":"84","author":"EJ Ley","year":"2018","unstructured":"Ley, E. J. et al. Beta blockers in critically ill patients with traumatic brain injury: Results from a multicenter, prospective, observational American Association for the Surgery of Trauma study. J. Trauma Acute Care Surg. 84, 234\u2013244 (2018).","journal-title":"J. Trauma Acute Care Surg."},{"key":"8736_CR26","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.cjca.2013.12.001","volume":"30","author":"L Poirier","year":"2014","unstructured":"Poirier, L. & Tobe, S. W. Contemporary use of \u03b2-blockers: Clinical relevance of subclassification. Can. J. Cardiol. 30, S9\u2013S15 (2014).","journal-title":"Can. J. Cardiol."},{"issue":"Suppl","key":"8736_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00543714","volume":"28","author":"A Westerlund","year":"1985","unstructured":"Westerlund, A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers. Eur. J. Clin. Pharmacol. 28(Suppl), 73\u201376 (1985).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"Suppl 2","key":"8736_CR28","first-page":"28","volume":"8","author":"U Borchard","year":"1990","unstructured":"Borchard, U. Pharmacokinetics of beta-adrenoceptor blocking agents: Clinical significance of hepatic and\/or renal clearance. Clin. Physiol. Biochem. 8(Suppl 2), 28\u201334 (1990).","journal-title":"Clin. Physiol. Biochem."},{"key":"8736_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(95)90694-0","volume":"345","author":"JN Townend","year":"1995","unstructured":"Townend, J. N. & Littler, W. A. Cardiac vagal activity: A target for intervention in heart disease. The Lancet 345, 937\u2013938 (1995).","journal-title":"The Lancet"},{"key":"8736_CR30","doi-asserted-by":"crossref","unstructured":"Kalinowski, L. et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 107, 2747\u20132752 (2003).","DOI":"10.1161\/01.CIR.0000066912.58385.DE"},{"key":"8736_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1573402114666180918102735","volume":"15","author":"GT do Vale","year":"2019","unstructured":"do Vale, G. T., Ceron, C. S., Gonzaga, N. A., Simplicio, J. A. & Padovan, J. C. Three generations of \u03b2-blockers: History, class differences and clinical applicability. Curr. Hypertens. Rev. 15, 22\u201331 (2019).","journal-title":"Curr. Hypertens. Rev."},{"key":"8736_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/FJC.0000000000000012","volume":"62","author":"ML Hess","year":"2013","unstructured":"Hess, M. L. & Varma, A. The third-generation beta-blocker: Have we found the elusive, effective antioxidant?. J. Cardiovasc. Pharmacol. 62, 443\u2013444 (2013).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"8736_CR33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.amjhyper.2004.03.668","volume":"17","author":"GP Vyssoulis","year":"2004","unstructured":"Vyssoulis, G. P. et al. The impact of third-generation Beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: Effects of smoking. Am. J. Hypertens. 17, 582\u2013589 (2004).","journal-title":"Am. J. Hypertens."},{"key":"8736_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11906-007-0050-2","volume":"9","author":"ME Pedersen","year":"2007","unstructured":"Pedersen, M. E. & Cockcroft, J. R. The vasodilatory beta-blockers. Curr. Hypertens. Rep. 9, 269\u2013277 (2007).","journal-title":"Curr. Hypertens. Rep."},{"key":"8736_CR35","unstructured":"Tucker, W. D., Sankar, P. & Theetha Kariyanna, P. Selective beta-1-blockers. In StatPearls (StatPearls Publishing, 2021)."},{"key":"8736_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1755-5922.2011.00306.x","volume":"31","author":"D Ladage","year":"2013","unstructured":"Ladage, D., Schwinger, R. H. G. & Brixius, K. Cardio-selective beta-blocker: Pharmacological evidence and their influence on exercise capacity. Cardiovasc. Ther. 31, 76\u201383 (2013).","journal-title":"Cardiovasc. Ther."},{"key":"8736_CR37","doi-asserted-by":"publisher","first-page":"169S","DOI":"10.1016\/j.amjhyper.2005.09.009","volume":"18","author":"MA Weber","year":"2005","unstructured":"Weber, M. A. The role of the new beta-blockers in treating cardiovascular disease. Am. J. Hypertens. 18, 169S-176S (2005).","journal-title":"Am. J. Hypertens."},{"key":"8736_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1751-7176.2009.00140.x","volume":"11","author":"C Manrique","year":"2009","unstructured":"Manrique, C., Giles, T. D., Ferdinand, K. C. & Sowers, J. R. Realities of newer beta-blockers for the management of hypertension. J. Clin. Hypertens. (Greenwich) 11, 369\u2013375 (2009).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"8736_CR39","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/00005344-200010000-00008","volume":"36","author":"P Schnabel","year":"2000","unstructured":"Schnabel, P. et al. Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors. J. Cardiovasc. Pharmacol. 36, 466\u2013471 (2000).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"8736_CR40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1751-7176.2011.00515.x","volume":"13","author":"WH Frishman","year":"2011","unstructured":"Frishman, W. H. & Saunders, E. \u03b2-Adrenergic blockers. J. Clin. Hypertens. (Greenwich) 13, 649\u2013653 (2011).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"8736_CR41","doi-asserted-by":"publisher","first-page":"10F","DOI":"10.1016\/0002-9149(87)90034-8","volume":"59","author":"DG McDevitt","year":"1987","unstructured":"McDevitt, D. G. Pharmacologic aspects of cardioselectivity in a beta-blocking drug. Am. J. Cardiol. 59, 10F-12F (1987).","journal-title":"Am. J. Cardiol."},{"key":"8736_CR42","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s00268-019-05058-z","volume":"43","author":"R Ahl","year":"2019","unstructured":"Ahl, R. et al. The relationship between severe complications, beta-blocker therapy and long-term survival following emergency surgery for colon cancer. World J. Surg. 43, 2527\u20132535 (2019).","journal-title":"World J. Surg."},{"key":"8736_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archsurg.2011.1698","volume":"147","author":"S Kwon","year":"2012","unstructured":"Kwon, S. et al. \u03b2-blocker continuation after noncardiac surgery: A report from the surgical care and outcomes assessment program. Arch. Surg. 147, 467\u2013473 (2012).","journal-title":"Arch. Surg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08736-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08736-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08736-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T19:44:33Z","timestamp":1669319073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08736-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8736"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08736-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"26 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5279"}}